Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Moderate Buy" by Analysts

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has received an average rating of "Moderate Buy" from the eight brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $28.00.

XNCR has been the topic of a number of recent research reports. Wedbush restated an "outperform" rating and set a $31.00 target price on shares of Xencor in a research note on Wednesday, April 30th. William Blair assumed coverage on shares of Xencor in a research report on Monday, April 21st. They set an "outperform" rating for the company. Wall Street Zen downgraded Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Finally, Barclays reduced their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research report on Thursday, May 8th.

Xencor Stock Performance

Shares of NASDAQ XNCR traded up $0.11 during midday trading on Thursday, reaching $8.41. 306,907 shares of the stock were exchanged, compared to its average volume of 677,673. The firm has a market cap of $598.18 million, a price-to-earnings ratio of -2.75 and a beta of 0.85. Xencor has a twelve month low of $7.16 and a twelve month high of $27.24. The company has a quick ratio of 5.89, a current ratio of 5.89 and a debt-to-equity ratio of 0.16. The firm has a 50-day simple moving average of $8.80 and a two-hundred day simple moving average of $13.64.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 181.17% and a negative return on equity of 31.94%. The business had revenue of $32.73 million for the quarter, compared to analysts' expectations of $23.44 million. During the same period in the prior year, the company posted ($1.11) EPS. The firm's revenue was up 104.6% on a year-over-year basis. As a group, analysts anticipate that Xencor will post -3.68 EPS for the current fiscal year.

Insider Buying and Selling

In other Xencor news, Director Ellen Feigal sold 2,993 shares of Xencor stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the transaction, the director owned 19,183 shares in the company, valued at approximately $176,867.26. The trade was a 13.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Nancy Valente sold 4,616 shares of the stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the sale, the executive vice president directly owned 49,169 shares in the company, valued at $542,334.07. This trade represents a 8.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 15,810 shares of company stock worth $154,123 over the last ninety days. Company insiders own 4.76% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Sterling Capital Management LLC grew its holdings in Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 1,040 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Xencor during the 4th quarter worth approximately $34,000. State of Wyoming acquired a new position in shares of Xencor during the 1st quarter worth about $34,000. CWM LLC boosted its position in Xencor by 195.5% during the first quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 2,231 shares during the last quarter. Finally, AlphaQuest LLC acquired a new position in Xencor during the first quarter worth $56,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.